Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals submitted its Monitoring Agency Report for the quarter ended June 30, 2026, detailing the utilization of proceeds from its prior preferential allotment.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
Fredun Pharmaceuticals submitted its Monitoring Agency Report for the quarter ended June 30, 2026, detailing the utilization of proceeds from its prior preferential allotment.
Fredun Pharmaceuticals filed its FY26 Annual Secretarial Compliance Report. The auditor noted temporary board composition non-compliance due to an executive director's sudden demise.
Fredun Pharmaceuticals Ltd submitted its quarterly compliance certificate under Regulation 74(5) for the period ended March 31, 2026. The report confirms that 1,000 shares belonging to Nikhil Vora and Sheela Vora were dematerialised during the quarter. This is a routine regulatory filing with no material impact on business operations.